Xconomy’s Digital Events →
Steve Paul acknowledged that gene therapy, despite its progress, is still in its early days. So is his company, Voyager Therapeutics—which is 14 months old yet is now poised for an IPO, as we wrote yesterday.
Sponsored · Whitepaper
New approaches & tech are on the horizon that could change how researchers and clinicians approach brain and neurological disorders
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
From Our Partners · Special Report
Advice for funding and future transformational opportunities
© 2007-2022, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.